Video

Dr. Jackson on Lenalidomide as a Highly-Effective Maintenance Therapy in Myeloma

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses results of a study that determined lenalidomide (Revlimid) is a highly-effective maintenance therapy in myeloma patients of all ages.

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses results of a study that determined lenalidomide (Revlimid) is a highly-effective maintenance therapy in myeloma patients of all ages.

In a study of about 850 patients, lenalidomide was found to increase progression-free survival (PFS). Across the entire cohort of patients, PFS increased by approximately 22 months. In the transplant eligible patients, PFS was increased by approximately 28 months. Even for the older population, the PFS increased by more than 12 months, Jackson says.

The results show that lenalidomide maintenance is now standard of care for frontline treatment in patients with myeloma, Jackson says.

Related Videos
David C. Fisher, MD
Binod Dhakal, MD
Ajay K. Nooka, MD, MPH, FACP
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.